Myopic Choroidal Neovascularization: Diagnosis and Treatment Update
- 15 Downloads
Purpose of Review
To review the diagnosis and treatment of myopic choroidal neovascularization. Imaging tests currently available and the advantages of each modality for detecting choroidal neovascularization signs are discussed. The management options and the outcomes of different treatment options are also reviewed.
Anti-vascular endothelial growth factor has become the preferable choice of treatment in myopic choroidal neovascularization cases with improved results. The benefits of a single injection followed by PRN dosing were supported by randomized clinical trials.
Choroidal neovascularization is a common vision threatening complication in patients with pathologic myopia. Most of the patients with this condition are younger than 50 years, and the major concern is to have vision preserved later in life. The investigation of myopic choroidal neovascularization imposes additional tests to be performed in most cases. Anti-vascular endothelial growth therapy has demonstrated superior efficacy over other treatment modalities. However, further studies are required for investigation of the risk factors for recurrences and the long-term treatment strategies.
KeywordsPathological myopia Degenerative myopia Choroidal neovascularization Optical coherence tomography Vascular endothelial growth factors
The editors thank Dr. André Freitas for lending his expertise and reviewing this manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S, NIH Center Core Grant P30EY014801, and Research to Prevent Blindness Unrestricted Grant.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Neelam K, Cheung CMG, Ohno-Matsui K, Lai TYY, Wong TY. Choroidal neovascularization in pathological myopia. Prog. Retin. Eye Res. Elsevier Ltd; 2012;31:495–525. Available from: https://doi.org/10.1016/j.preteyeres.2012.04.001.
- 2.•• Tan NW, Ohno-Matsui K, Koh HJ, Nagai Y, Pedros M, Freitas RL, et al. Long-term outcomes of ranibizumab treatment of myopic choroidal neovascularization in East-Asian patients from the radiance study. Retina. 2018;38(11):2228-382238. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221407. The study confirmed the long-term effectiveness of Ranibizumab over an additional 36 months of follow up in a cohort of East-Asian patients from the RADIANCE study.
- 3.Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology. 2002;109:704–11. https://www.aaojournal.org/article/S0161-6420(01)01024-7/fulltext
- 6.Liu HH, Xu L, Wang YX, Wang S, You QS, Jonas JB. Prevalence and progression of myopic retinopathy in Chinese adults: The Beijing eye study. Ophthalmolog. Elsevier Inc.; 2010;117:1763–1768. Available from: https://doi.org/10.1016/j.ophtha.2010.01.020.
- 8.Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am. J. Ophthalmol. 2014;157:9–25.e12 Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002939413005473.CrossRefGoogle Scholar
- 9.Ng DSC, Lai TYY, Cheung CMG, Ohno-Matsui K. Anti–vascular endothelial growth factor therapy for myopic choroidal neovascularization. Asia-Pacific J. Ophthalmol. 2017:1741–6 Available from: http://www.apjo.org/Apjo/pdf/id/551.html.
- 13.Willis JR, Vitale S, Morse L, Parke DW, Rich WL, Lum F, et al. The prevalence of myopic choroidal neovascularization in the United States: analysis of the IRIS(®) data registry and NHANES. Ophthalmology. 2016;123:1771–82 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27342789.CrossRefGoogle Scholar
- 14.Chan W, Ohji M, Lai TYY, Liu DTL, Tano Y, Lam DSC. Choroidal neovascularisation in pathological myopia - an update in management. Br J Ophthalmol. 2005;89(11):1522–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1772951.
- 16.Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015;99:289–96. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345796/.
- 17.Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003;110:1297–305. https://www.aaojournal.org/article/S0161-6420(03)00461-5/fulltext.
- 18.Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol. 2003;87:570–3. https://bjo.bmj.com/content/87/5/570.long
- 19.Leveziel N, Gaucher D, Baillif S, Benouaich X, Chartier C, Grenet T, et al. Understanding the determinants of myopic choroidal neovascularization and response to treatment. Eur J Ophthalmol. 2016;26:511–6. https://www.ncbi.nlm.nih.gov/pubmed/27515571.
- 20.Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina. 2015;35:2252–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26457400.CrossRefGoogle Scholar
- 21.Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001;108:841–52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11320011.CrossRefGoogle Scholar
- 22.Leveziel N, Caillaux V, Bastuji-Garin S, Zmuda M, Souied EH. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am. J. Ophthalmol. 2013:913–919.e1 Available from: http://linkinghub.elsevier.com/retrieve/pii/S000293941200832X.
- 24.• Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, et al. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology [Internet]. American Academy of Ophthalmology; 2017;124:1690–711. Available from: https://doi.org/10.1016/j.ophtha.2017.04.028. The article review and assemble information about myopic choroidal neovascularization concepts and recently developed treatments.
- 25.Keane PA, Chang KT, Walsh AC. NIH public access. Reading. 2009;92:1081–5.Google Scholar
- 26.Guyer D, Yannuzzi L, Slakter J, Al E. Diagnostic indocyanine green angiography videoangiography. In: Ryan SJ, Schachat AP, eds. Retina. 3. St. Louis, MO: Mosby; 2001. p. 943–66.Google Scholar
- 28.Lai TYY, Luk FOJ, Lee GKY, Lam DSC. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye (Lond). 2012;26:1004–11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22595908.CrossRefGoogle Scholar
- 29.Miyake M, Yamashiro K, Akagi-Kurashige Y, Kumagai K, Nakata I, Nakanishi H, et al. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia. Ophthalmology. 2014;121:225–33 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23953100.
- 31.Lai TYY, Cheung CMG. Myopic choroidal neovascularization diagnosis and treatment. Retina. 2016;36:1614–21. https://www.ncbi.nlm.nih.gov/pubmed/27482641
- 32.Lumbroso B, Rispoli M, Savastano MC. Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment. Retina. 2015;35:2242–51. https://www.ncbi.nlm.nih.gov/pubmed/26457401.
- 33.Querques L, Giuffrè C, Corvi F, Zucchiatti I, Carnevali A, De Vitis LA, et al. Optical coherence tomography angiography of myopic choroidal neovascularisation. Br J Ophthalmol. 2017;101:609–15. https://www.ncbi.nlm.nih.gov/pubmed/27531357.
- 37.Glacet-Bernard A, Simon P, Hamelin N, Coscas G, Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am. J. Ophthalmol. 2001;131:78–89 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11162982.CrossRefGoogle Scholar
- 38.Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv. Ophthalmol. 53:121–38 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18348878.
- 39.Fujikado T, Ohji M, Kusaka S, Hayashi A, Kamei M, Okada AA, et al. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am. J. Ophthalmol. 2001;131:101–10 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11162984.CrossRefGoogle Scholar
- 41.Ruiz-Moreno JM, Montero JA. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur. J. Ophthalmol. 12:117–22 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12022283.
- 42.Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195–214. https://www.ncbi.nlm.nih.gov/pubmed/11094244.
- 43.Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110:667–73 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12689884.CrossRefGoogle Scholar
- 44.Montero JA, Ruiz-Moreno JM. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol. 2003;87:173–6. https://bjo.bmj.com/content/87/2/173.long.
- 45.Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014;121:682–92. https://www.ncbi.nlm.nih.gov/pubmed/24326106.
- 46.Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye [internet]. Nat Publ Group. 2013;27:709–15. Available from:. https://doi.org/10.1038/eye.2013.8.
- 47.Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the repair study. Ophthalmology. 2013;120:1944–6. https://www.aaojournal.org/article/S0161-6420(13)00501-0/fulltext.
- 52.Wu TT, Kung YH. Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization. Retina. 2017;37:2056–61. https://www.ncbi.nlm.nih.gov/pubmed/28590318.
- 53.Ceklic L, Munk MR, Wolf-Schnurrbusch U, Gekkieva M, Wolf S. Visual acuity outcomes of ranibizumab treatment in pathologic myopic eyes with macular retinoschisis and choroidal neovascularization. Retina. 2017;37:687–93. https://www.ncbi.nlm.nih.gov/pubmed/27533774.